Avidity gets FDA partial clinical hold lifted on DM1 drug candidate [Seeking Alpha]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Seeking Alpha
known as del-desiran and AOC 1001, for the treatment of myotonic dystrophy type 1, or DM1. The therapy is being evaluated in an ongoing Phase 3 study called HARBOR. Del-desiran has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA. Other companies working on treatments for DM1 include Vertex Pharmaceuticals ( VRTX ), Dyne Therapeutics ( DYN ) and PepGen ( PEPG More on Avidity Biosciences Avidity Biosciences: Good Prospects, But We Are A Little Late Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders Avidity Biosciences prices $300.1M upsized equity offering Seeking Alpha's Quant Rating on Avidity Biosciences Recommended For You Comments More Trending News Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $72.00 price target on the stock.MarketBeat
- Avidity Biosciences to Participate in Upcoming Investor ConferencePR Newswire
- Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $67.00 price target on the stock.MarketBeat
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
RNA
Earnings
- 8/9/24 - Beat
RNA
Sec Filings
- 12/19/24 - Form 4
- 12/19/24 - Form 4
- 12/19/24 - Form 4
- RNA's page on the SEC website